

Practitioner's Docket No. MPI00-544OMNICN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of:	Holtzman, Douglas A., et al		
Application No.:	10/806,018	Group No.:	1646
Filed:	March 22, 2004	Examiner:	Pak, Michael D.
For:	NOVEL ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, AND STMST PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREFOR		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker

(type or print name of person certifying)

Date: October 4, 2006

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-544OMNICN1M

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

☐ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☐ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI00-544OMNICN1M

FEE PAYMENT


3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

		Fee due	\$0.00
METHOD OF PAYMENT OF FEE			
4. <input type="checkbox"/> Attached is a check in the amount of \$ _____.			
<input checked="" type="checkbox"/> Charge Account No. 501668 in the amount of		\$0.00	.

☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

<u>October 4, 2006</u>	MILLENNIUM PHARMACEUTICALS, INC. By <u></u> Mario Cloutier Registration No. 57,225 40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-577-3522 Facsimile - 617-551-8820
------------------------	---

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MNI-073CP	SERIAL NO. 09/448,076
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)			APPLICANT Mehran M. Khodadoust and Kyle J. MacBeth	
			FILING DATE November 23, 1999	GROUP 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
AB					

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

AC	Bedell-Hogan, Debra et al., "Oxidation, cross-linking, and insolubilization of recombinant tropoelastin by purified lysyl oxidase", <i>Journal of Biological Chemistry</i> , 268(14) :10345-10350 (1993);
AD	Chengzhen, R. et al. "Reduced Lysyl Oxidase Messenger RNA Levels in Experimental and Human Prostrate Cancer" <i>Cancer Res.</i> 58 :1285-1290
AE	Copy of Blast™ Search using Soares_placenta_8to9weeks_2NbHP8to9W Homo sapiens cDNA clone IMAGE:1714162 3';
AF	Copy of Blast™ Search using Mus musculus lysyl oxidase-related protein 2 (Lor 2) mRNA, complete cds;
AG	Copy of Blast™ Search using Soares_placenta_8to 9weeks_2NbHP8to9W Homo Sapiens cDNA clone IMAGE:1714162 3';
AH	Copy of Blast™ Search using lysyl oxidase-related protein 2 [Mus musculus] length = 754;
AI	Copy of Blast™ Search using Barstead mouse were not reported due to the limiting value of parameter V = 10;
AJ	Dangott, Lawrence J. et al. "Cloning of the mRNA for the protein that crosslinks to the egg peptide speract", <i>Proc. Natl. Acad. Sci. USA</i> , 86 :2128-2132 (1989);
AK	Freeman, Mason et al. "An ancient, highly conserved family of cysteine-rich protein domains reveled by cloning type I and type II murine macrophage scavenger receptors", <i>Proc. Natl. Acad. Sci. USA</i> , 87 :8810-8814 (1990);
AL	GenBank® Accession Number AA269410 for Soares mouse 3NME12 5 Mus musculus cDNA clone 6-OXIDASE PRECURSOR;
AM	GenBank® Accession Number AA369741 for Pancreas tumor II Homo sapiens cDNA 5" end;
AN	GenBank® Accession Number AA522066 for Barstead mouse myotubes MPLRB5 Mus musculus cDNA clone IMAGE:903231 5' similar to SW:WC11_BOVIN P30205 ANTIGEN WC1.1;
AO	GenBank® Accession Number AA530866 for NCI_CGAP_Pr21 Homo sapiens cDNA clone IMAGE:984748 3';

Examiner	Date Considered
----------	-----------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MNI-073CP	SERIAL NO. 09/448,076
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Mehran M. Khodadoust and Kyle J. MacBeth	
		FILING DATE November 23, 1999	GROUP 1643

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	BA	GenBank® Accession Number AA625414 for Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:1047259 af69b10.r1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:1047259 5';
	BB	GenBank® Accession Number AA673141 for Soares mouse mammary gland NbMMG Mus musculus cDNA clone IMAGE:820637 5';
	BC	GenBank® Accession Number for AA792234 for Soares mouse mammary gland NbMMG Mus musculus cDNA clone complete cds (MOUSE);
	BD	GenBank® Accession Number AA852888 for normal Human Trabecular Bone Cells Homo sapiens cDNA clone NHTBCae01a08;
	BE	GenBank® Accession Number AA852889 for normal Human Trabecular Bone Cells Homo sapiens cDNA clone NHTBCae01a08;
	BF	GenBank® Accession Number AI082055 for Soares_senescent_fibroblasts_HbHSF Homo sapiens cDNA clone IMAGE:1678980 3' similar to TR:Q08397 Q08397 PROTEIN-LYSINE OXIDASE HOMOLOG PRECURSOR; contains TR1.t1 MSR1 repetitive element;
	BG	GenBank® Accession Number AI148499 for Soares_placenta_8to9weeks_2NBHP8to9W Homo sapiens cDNA clone IMAGE:171462 3';
	BH	GenBank® Accession Number AI180353 for normalized rat spleen, Bento Soares Rattus sp. CDNA clone RSPCV22 3' end;
	BI	GenBank® Accession Number AAI249780 for NCI_CGAP_Pan1 Homo sapiens cDNA clone IMAGE:2004863 3' similar to TR:Q60997 Q60997 CRP-DUCTIN PRECURSOR; contains TAR1.t1 TAR1 repetitive element;
	BJ	GenBank® Accession Number AI251754 for Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:1854302 3';
	BK	GenBank® Accession Number AI262314 for NCI_CGAP_Co8 Homo sapiens cDNA clone IMAGE:1870845 3';
	BL	GenBank® Accession Number AI291580 for Soares_placenta_8to9weeks_2NbHP8to9W Homo sapiens cDNA clone IMAGE:1894465 3';
	BM	GenBank® Accession Number AI291685 for Soares_placenta_8to9weeks_2NbHP8to9W Homo sapiens cDNA clone IMAGE:1894522 3';
	BN	GenBank® Accession Number AAB49697 for lysyl oxidase-related protein;
	BO	GenBank® Accession Number AAC79085 for lysyl oxidase homolog;
	BP	GenBank® Accession Number AAC83205 for lysyl oxidase-related protein 2;
	BQ	GenBank® Accession Number AAC95338 for LOR2 protein;
Examiner		Date Considered
*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MNI-073CP	SERIAL NO. 09/448,076
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Mehran M. Khodadoust and Kyle J. MacBeth	
		FILING DATE November 23, 1999	GROUP 1643

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

	CA	GenBank® Accession Number AC003061 for Mouse chromosome 6 BAC Clone b245c12, complete sequence;
	CB	GenBank® Accession Number AC005033 for Homo sapiens clone NH0140K04, complete sequence;
	CC	GenBank® Accession Number AC005041 for Homo sapiens clone NH0523H20, complete sequence;
	CD	GenBank® Accession Number AF053368 for Mus musculus lysyl oxidase-related protein 2 (Lor2) mRNA, complete cds.
	CE	GenBank® Accession Number AF084363 for Mus musculus D6MM5e protein (D6Mm5e) and DOK protein (Dok) genes, complete cds; and LOR2 protein (Lor2) gene, partial cds;
	CF	GenBank® Accession Number AF103901 for Perca flavescens lysyl oxidase homolog (PLO1) mRNA, partial cds;
	CG	GenBank® Accession Number HSU89942 for Human Lysyl oxidase-related protein (WS9-14) mRNA, complete cds;
	CH	Hämäläinen, Eija-Riitta et al., "Molecular cloning of human lysyl oxidase and assignment of the gene to chromosome 5a23.3-31.2", <i>Genomics</i> , 11 :508-516 (1991);
	CI	Jang, Wonhee et al., "Comparative sequence of human and mouse BAC clones the <i>mnd2</i> region of Chromosome 2p13", <i>Cold Spring Harbor Laboratory Press</i> , 9 :53-61 (1999);
	CJ	Jourdan-LeSaux, Claude et al., "The LOXL2 gene encodes a new lysyl oxidase-like protein and is expressed at high levels in reproductive tissues", <i>Journal of Biological Chemistry</i> , 274 (18):12939-12944 (1999);
	CK	Kagan, H.M. et al., "Catalytic properties and structural components of lysyl oxidase" from Ciba Foundation Symposium: <i>The molecular biology and pathology of elastic tissues. Ciba Foundation Symposium 192</i> , pp. 100-121 (1995);
	CL	Kenyon, Kaylene et al., "A novel human cDNA with a predicted protein similar to lysyl oxidase maps to chromosome 15q24-q25", <i>Journal of Biological Chemistry</i> , 268 (5):18435-18437 (1993);
	CM	Kim, Youngho et al., "Coexpression of the lysyl oxidase-like gene (LOXL) and the gene encoding type II procollagen in induced liver fibrosis", <i>Journal of Cellular Biochemistry</i> , 72 :181-188 (1999);
	CN	Kim, Youngho et al., "A new gene with sequence and structural similarity to the gene encoding human lysyl oxidase", <i>Journal of Biological Chemistry</i> , 270 (13):7176-7182 (1995);
	CO	Saito, Hiroshi et al., "Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence", <i>Journal of Biological Chemistry</i> , 272 (13):8157-8160 (1997);
	CP	Somers, Shaw S. et al., "Comparison of transforming growth factor β and a human tumour-derived suppressor factor", <i>Cancer Immunology Immunotherapy</i> , pp. 217-222 (1991);
	CQ	Trackman, Philip C. et al., "Cloning of rat aorta lysyl oxidase cDNA: complete codons and predicted amino acid sequence", <i>Biochemistry</i> , 29 :4863-4870 (1990);
Examiner		Date Considered
*EXAMINER : Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

+

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1995, no persons are required to

DISCLOSURE
OCT 10 2006
TRADEMARK

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/806,018
Filing Date	March 22, 2004
First Named Inventor	Holtzman, Douglas A.
Group Art Unit	1646
Examiner Name	Michael D. Pak
Attorney Docket Number	MPI00-544OMN1CN1M

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

Date	
Considered	

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

+